Aldeyra Therapeutics shares rise 32.08% after hours as FDA delays Reproxalap decision to March 2026 without raising new issues.

Aldeyra Therapeutics surged 32.08% in after-hours trading following the FDA’s extension of the PDUFA review date for its dry eye drug Reproxalap to March 16, 2026. The delay, triggered by the FDA’s request for a previously reviewed clinical study report, was classified as a major amendment but did not introduce new issues. The agency shared a draft label and outlined next steps, signaling continued regulatory progress. Despite the extension, the absence of new concerns and ongoing dialogue with the FDA alleviated investor fears, fueling the sharp post-market rally. The stock’s performance contrasts with a pre-market decline mentioned in some reports, likely reflecting evolving interpretations of the FDA’s feedback during the day.